New drug combo aims to shrink lung tumors in early trial

NCT ID NCT06448754

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests a new drug called volrustomig combined with other cancer treatments for people with advanced non-small cell lung cancer. The main goals are to check safety and see if tumors shrink. About 180 adults will take part in this early-stage trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    COMPLETED

    Los Angeles, California, 90067, United States

  • Research Site

    WITHDRAWN

    Grand Junction, Colorado, 81501, United States

  • Research Site

    WITHDRAWN

    Wheat Ridge, Colorado, 80033, United States

  • Research Site

    WITHDRAWN

    Baltimore, Maryland, 21231, United States

  • Research Site

    WITHDRAWN

    Detroit, Michigan, 48202, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • Research Site

    WITHDRAWN

    Tacoma, Washington, 98405, United States

  • Research Site

    WITHDRAWN

    Montreal, Quebec, H4A 3J1, Canada

  • Research Site

    RECRUITING

    Beijing, 100730, China

  • Research Site

    RECRUITING

    Hangzhou, 310014, China

  • Research Site

    RECRUITING

    Jinan, 250013, China

  • Research Site

    RECRUITING

    Yantai, 264000, China

  • Research Site

    RECRUITING

    Zhengzhou, 450000, China

  • Research Site

    RECRUITING

    Bois-Guillaume, 76031, France

  • Research Site

    RECRUITING

    Caen, 14076, France

  • Research Site

    WITHDRAWN

    Créteil, 94000, France

  • Research Site

    RECRUITING

    Dijon, 21079, France

  • Research Site

    RECRUITING

    Montpellier, 34070, France

  • Research Site

    RECRUITING

    Batumi, 6010, Georgia

  • Research Site

    RECRUITING

    Tbilisi, '0159, Georgia

  • Research Site

    RECRUITING

    Tbilisi, 0112, Georgia

  • Research Site

    RECRUITING

    Tbilisi, 0114, Georgia

  • Research Site

    RECRUITING

    Tbilisi, 0144, Georgia

  • Research Site

    RECRUITING

    Tbilisi, 186, Georgia

  • Research Site

    RECRUITING

    Athens, 115 27, Greece

  • Research Site

    RECRUITING

    Athens, 12462, Greece

  • Research Site

    RECRUITING

    Elaiones, 546 23, Greece

  • Research Site

    RECRUITING

    Piraeus, 185 47, Greece

  • Research Site

    RECRUITING

    Thessaloniki, 57001, Greece

  • Research Site

    RECRUITING

    Genoa, 16132, Italy

  • Research Site

    RECRUITING

    Meldola, 47014, Italy

  • Research Site

    RECRUITING

    Milan, 20133, Italy

  • Research Site

    RECRUITING

    Naples, 80131, Italy

  • Research Site

    RECRUITING

    Orbassano, 10043, Italy

  • Research Site

    RECRUITING

    Perugia, 06132, Italy

  • Research Site

    RECRUITING

    Rozzano, 20089, Italy

  • Research Site

    RECRUITING

    Udine, 33100, Italy

  • Research Site

    RECRUITING

    Verona, 37134, Italy

  • Research Site

    RECRUITING

    Kuala Lumpur, 59100, Malaysia

  • Research Site

    RECRUITING

    Kuching, 93586, Malaysia

  • Research Site

    RECRUITING

    Perai, 13700, Malaysia

  • Research Site

    RECRUITING

    Lisbon, 1169-050, Portugal

  • Research Site

    RECRUITING

    Lisbon, 1400-038, Portugal

  • Research Site

    WITHDRAWN

    Lisbon, 1500-458, Portugal

  • Research Site

    RECRUITING

    Lisbon, 1649-035, Portugal

  • Research Site

    RECRUITING

    Porto, 4099-001, Portugal

  • Research Site

    WITHDRAWN

    Porto, 4100-180, Portugal

  • Research Site

    RECRUITING

    Cluj-Napoca, 400641, Romania

  • Research Site

    RECRUITING

    Craiova, 200542, Romania

  • Research Site

    RECRUITING

    Floreşti, 407280, Romania

  • Research Site

    WITHDRAWN

    Belgrade, 11000, Serbia

  • Research Site

    RECRUITING

    Belgrade, 11000, Serbia

  • Research Site

    WITHDRAWN

    Kamenitz, 21204, Serbia

  • Research Site

    WITHDRAWN

    Kragujevac, 34000, Serbia

  • Research Site

    COMPLETED

    Seongnam, 13620, South Korea

  • Research Site

    RECRUITING

    Seoul, 03722, South Korea

  • Research Site

    WITHDRAWN

    Seoul, 06591, South Korea

  • Research Site

    RECRUITING

    Suwon, 16247, South Korea

  • Research Site

    RECRUITING

    A Coruña, 15009, Spain

  • Research Site

    RECRUITING

    Alcorcón, 28922, Spain

  • Research Site

    RECRUITING

    Barcelona, 08041, Spain

  • Research Site

    RECRUITING

    Madrid, 28041, Spain

  • Research Site

    RECRUITING

    Málaga, 29004, Spain

  • Research Site

    RECRUITING

    Pamplona, 31008, Spain

  • Research Site

    RECRUITING

    Santander, 39008, Spain

  • Research Site

    RECRUITING

    Santiago de Compostela, 15706, Spain

  • Research Site

    RECRUITING

    Valencia, 46015, Spain

  • Research Site

    RECRUITING

    Valencia, 46026, Spain

  • Research Site

    WITHDRAWN

    Basel, 4031, Switzerland

  • Research Site

    RECRUITING

    Geneva, 1205, Switzerland

  • Research Site

    RECRUITING

    Lausanne, 1011, Switzerland

  • Research Site

    RECRUITING

    Winterthur, 8401, Switzerland

  • Research Site

    RECRUITING

    Zurich, 8091, Switzerland

  • Research Site

    RECRUITING

    Changhua, 50006, Taiwan

  • Research Site

    RECRUITING

    New Taipei City, 23561, Taiwan

  • Research Site

    RECRUITING

    Taipei, 106, Taiwan

  • Research Site

    RECRUITING

    Taipei, 110, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.